MEDICAL DEVICE

Celleration^TM is developing novel technologies for the therapeutic treatment of chronic wounds. Celleration's core technology is a patented non-imaging, non-contact ultrasound system called Mist Ultra Sound Transport^TM that the company believes significantly speeds the healing of chronic wounds.

Incept BioSystems develops innovative microscale and nanoscale technologies that provide cell biologists the ability to obtain high value data about cell growth and behavior. Our technologies were developed to improve the in vitro manipulation, performance, and viability of high-value cells, and our vision is to become the next-generation stardard for Premium Cell Management applications.

IntraLase (Nasdaq: ILSE) is a medical devices company that has developed an automated procedure for laser vision correction. The "IntraLasik" procedure will be the industry's first all laser surgery. Their device will eliminate the need for a mechanical microkeratome. IntraLase was acquired by Advanced Medical Optics (NYSE: EYE) in March 2007.

Nerites Corporation is an innovative medical technology company that develops novel tissue repair products and coatings for medical devices. Our products are being developed to impact all fields where medical devices are used.

At Nerites, we produce the only synthetic water resistant adhesive available. Bench studies have demonstrated our technology’s maintenance of adhesive performance during many cycles of full immersion in water. Our coatings are being developed to improve the performance of existing medical devices by preventing bacterial adhesion and supporting tissue repair.

NeuWave Medical is a University of Wisconsin start-up that develops minimally invasive technologies for the treatment of cancer. NeuWave’s core technology is a proprietary microwave ablation system that provides substantial benefits over traditional thermal ablation techniques.

TomoTherapy (Nasdaq: TTPY) develops, manufactures and markets a leading system for precision delivery of radiation therapy to cancer patients. Their Hi·Art (Highly Integrated Adaptive RadioTherapy) System® integrates treatment planning, patient positioning, and treatment delivery in one system. The Hi·Art System® provides unparalleled precision in dose delivery to the tumor and conformal avoidance of vital healthy tissue with a highly efficient patient throughput.

Tissue Regeneration Systems, Inc (TRS) is developing bioactive medical devices for bone and soft tissue regeneration. The Company is a spin-out of the Universities of Michigan and Wisconsin, where TRS’ core proprietary technologies were developed over the past decade. TRS’ first products are in the spine and craniofacial markets.